North Run Capital’s Teva Pharmaceuticals TEVA Stock Holding History

North Run Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,070,000	Closed	-$38.8M	–	21
2016 Q4	$38.8M	Buy	1,070,000 +255,000	+31%	+$10.2M	11.85%	3
2016 Q3	$37.5M	Sell	815,000 -40,000	-5%	-$2.09M	5.89%	7
2016 Q2	$42.9M	Sell	855,000 -15,000	-2%	-$799K	7.08%	2
2016 Q1	$46.6M	Buy	870,000 +45,000	+5%	+$2.64M	6.38%	5
2015 Q4	$54.2M	Sell	825,000 -200,000	-20%	-$12.4M	6.39%	5
2015 Q3	$57.9M	Buy	1,025,000 +125,000	+14%	+$8.1M	5.68%	5
2015 Q2	$53.2M	Buy	900,000 +150,000	+20%	+$9.25M	5.22%	6
2015 Q1	$46.7M	Hold	750,000	–	–	5.11%	10
2014 Q4	$43.1M	Hold	750,000	–	–	3.84%	13
2014 Q3	$40.3M	Sell	750,000 -110,000	-13%	-$5.83M	3.65%	13
2014 Q2	$45.1M	Sell	860,000 -315,000	-27%	-$16.1M	4.38%	13
2014 Q1	$62.1M	Sell	1,175,000 -1,175,000	-50%	-$54.3M	6.31%	2
2013 Q4	$94.2M	Buy	+2,350,000	New	+$92.5M	11.93%	1

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

North Run Capital's TEVA Position: Q1 2017 in Review

North Run Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 1,070,000 shares — an estimated $38.8M sold.

North Run Capital first reported a position in TEVA in Q4 2013 and held it in 13 quarters. The position peaked at $94.2M in Q4 2013. 687 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

North Run Capital reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
North Run Capital sold 1,070,000 Teva Pharmaceuticals shares in Q1 2017, an estimated $38.8M.
North Run Capital first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 13 quarters.
North Run Capital's Teva Pharmaceuticals position peaked at $94.2M in Q4 2013.
687 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on North Run Capital's 13F filing for Q1 2017, filed 12 May 2017.